ArriVent BioPharma, Inc. (AVBP) vs MannKind Corporation (MNKD)
A side-by-side comparison of ArriVent BioPharma, Inc. and MannKind Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$12.89HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
MNKD
MannKind Corporation
$3.82HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — AVBP vs MNKD
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)MNKD +14.0% (+4.5%/yr)AVBP compounded faster over this window
AVBP MNKD
AVBP vs MNKD: by the numbers
- •MNKD is the larger company ($1.22B vs $600M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -11.08% net margin).
Metrics side by side
Valuation
| Metric | AVBP | MNKD |
|---|---|---|
| P/S ratio | N/A | 3.10 |
| P/B ratio | 1.64 | N/A |
| EV / EBITDA | N/A | 52.41 |
Profitability
| Metric | AVBP | MNKD |
|---|---|---|
| Gross margin | 0.00% | 75.69% |
| Operating margin | 0.00% | 11.12% |
| Net margin | 0.00% | -11.08% |
| ROE | -44.63% | N/A |
| ROIC | -47.96% | 1.32% |
Growth (annualized)
| Metric | AVBP | MNKD |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 39.51% |
| Total return CAGR (5Y) | N/A | -4.18% |
Go deeper
Dig into the metrics
ArriVent BioPharma ROEMannKind ROEArriVent BioPharma operating marginMannKind operating marginArriVent BioPharma revenue growthMannKind revenue growthArriVent BioPharma free cash flowMannKind free cash flow
ArriVent BioPharma & MannKind appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.